Hologic Inc. (NASDAQ:HOLX)‘s stock had its “outperform” rating reiterated by equities researchers at Leerink Swann in a note issued to investors on Monday. They presently have a $46.00 target price on the stock. Leerink Swann’s target price would suggest a potential upside of 18.47% from the company’s previous close.
Several other equities research analysts have also recently issued reports on the stock. Zacks Investment Research upgraded shares of Hologic from a “hold” rating to a “buy” rating and set a $43.00 price objective for the company in a research report on Wednesday, September 28th. Barclays PLC upgraded shares of Hologic from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $42.00 to $44.00 in a research report on Friday, September 23rd. Piper Jaffray Cos. set a $44.00 target price on shares of Hologic and gave the stock a “hold” rating in a research note on Sunday, August 28th. RBC Capital Markets reaffirmed a “sector perform” rating and set a $39.00 target price (up previously from $37.00) on shares of Hologic in a research note on Monday, August 1st. Finally, Royal Bank Of Canada increased their target price on shares of Hologic from $37.00 to $39.00 and gave the stock a “sector perform” rating in a research note on Monday, August 1st. Six analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Hologic presently has a consensus rating of “Buy” and a consensus target price of $42.71.
Hologic (NASDAQ:HOLX) traded down 0.59% during midday trading on Monday, hitting $38.60. 942,075 shares of the stock traded hands. The company’s 50-day moving average is $38.32 and its 200 day moving average is $36.04. The firm has a market cap of $10.71 billion, a P/E ratio of 42.56 and a beta of 1.00. Hologic has a 12-month low of $31.84 and a 12-month high of $41.66.
Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, July 27th. The company reported $0.51 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.48 by $0.03. Hologic had a net margin of 9.39% and a return on equity of 26.25%. The firm earned $717.40 million during the quarter, compared to analysts’ expectations of $703.66 million. During the same period last year, the business earned $0.43 earnings per share. Hologic’s revenue was up 3.4% compared to the same quarter last year. On average, analysts anticipate that Hologic will post $1.94 EPS for the current fiscal year.
In other Hologic news, Director Nancy Leaming sold 8,179 shares of the firm’s stock in a transaction that occurred on Thursday, July 21st. The shares were sold at an average price of $37.00, for a total transaction of $302,623.00. Following the sale, the director now owns 67,140 shares of the company’s stock, valued at $2,484,180. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.84% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the company. Kentucky Retirement Systems Insurance Trust Fund bought a new stake in Hologic during the second quarter worth $339,000. Kentucky Retirement Systems acquired a new position in shares of Hologic during the second quarter worth approximately $714,000. Mason Street Advisors LLC acquired a new position in shares of Hologic during the second quarter worth approximately $1,131,000. Public Employees Retirement System of Ohio boosted its position in shares of Hologic by 5.5% in the second quarter. Public Employees Retirement System of Ohio now owns 98,865 shares of the company’s stock worth $3,421,000 after buying an additional 5,182 shares during the last quarter. Finally, Calvert Investment Management Inc. boosted its position in shares of Hologic by 0.8% in the second quarter. Calvert Investment Management Inc. now owns 15,244 shares of the company’s stock worth $527,000 after buying an additional 122 shares during the last quarter. 94.51% of the stock is currently owned by institutional investors.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.